The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Evening.
This genome UK was launched today.Although it us not directly relevant here does talk about personalised medicine in cancer is being a big priority and it may be that some of SCLP work will find particular favour.
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/920378/Genome_UK_-_the_future_of_healthcare.pdf
Bunsie,
The science at SNG is somewhat straightforward but also rather brilliant. My fear for SNG is lack of funding, so hopefully they might be able to cut a deal somehow and get the drug through stage 3. That is unlikely to happen before May 2021 IMO unless big pharma are feeling generous. I believe the SP is likely to drift, hence why I have taken most of my profits from there and parked them with SCLP.
Inan,
Thanks for your full response. This was the reason I posted the article to see if there was more to interferons than I was aware of. For instance I had not looked at interferon gamma before now. Following your post here I have a better understanding of the basic principles of interferons and immune response. I am still learning and I appreciate the effort you and others make to help me better understand the science here. I have lots of reading to do!
Many Thanks
but of course those that like holding many shares, one to watch
anyway impressed with Synair .. and if i had space in my ISA i would include them, however Scancell is a way bigger player with its potential from a returns point of view ..
that was the bit i was after...
""" All interferons significantly enhance the presentation of MHC I dependent antigens"""
so synair could act as a primer for an adaptive response
got it now ........
All interferons share several common effects: they are antiviral agents and they modulate functions of the immune system. Administration of Type I IFN has been shown experimentally to inhibit tumor growth in animals, but the beneficial action in human tumors has not been widely documented. A virus-infected cell releases viral particles that can infect nearby cells. However, the infected cell can protect neighboring cells against a potential infection of the virus by releasing interferons. In response to interferon, cells produce large amounts of an enzyme known as protein kinase R (PKR). This enzyme phosphorylates a protein known as eIF-2 in response to new viral infections; the phosphorylated eIF-2 forms an inactive complex with another protein, called eIF2B, to reduce protein synthesis within the cell. Another cellular enzyme, RNAse L—also induced by interferon action—destroys RNA within the cells to further reduce protein synthesis of both viral and host genes. Inhibited protein synthesis impairs both virus replication and infected host cells. In addition, interferons induce production of hundreds of other proteins—known collectively as interferon-stimulated genes (ISGs)—that have roles in combating viruses and other actions produced by interferon.[12][13] They also limit viral spread by increasing p53 activity, which kills virus-infected cells by promoting apoptosis.[14][15] The effect of IFN on p53 is also linked to its protective role against certain cancers.[14]
Another function of interferons is to up-regulate major histocompatibility complex molecules, MHC I and MHC II, and increase immunoproteasome activity. All interferons significantly enhance the presentation of MHC I dependent antigens. Interferon gamma (IFN-gamma) also significantly stimulates the MHC II-dependent presentation of antigens. Higher MHC I expression increases presentation of viral and abnormal peptides from cancer cells to cytotoxic T cells, while the immunoproteasome processes these peptides for loading onto the MHC I molecule, thereby increasing the recognition and killing of infected or malignant cells. Higher MHC II expression increases presentation of these peptides to helper T cells; these cells release cytokines (such as more interferons and interleukins, among others) that signal to and co-ordinate the activity of other immune cells
https://en.wikipedia.org/wiki/Interferon#:~:text=A%20virus%2Dinfected%20cell%20releases,protein%20kinase%20R%20(PKR).
Bojo,
I think you are looking at SNG001 as a treatment, Interferon Beta, which Covid19 switches off... yes worthy of a look and further research.
ATB
Bunsie
there are 4 or 5 interferon ...the original article did not specify .
that synair data is impressive not studied beta, but i suspect the immune system responds also to that call for help .. cytokine
which is what Gamma does ... which also has the same anti viral effect
Yes, as we are looking at a vaccine?
from Scancels perspective the Virus is instantly recognised so never get the chance to fox the immune system
COVID effectively switches off the bodies ability to produce interferons as part of its natural immune repsonse. Now as you may or may not know, there are trials underway that are looking at reintroducing interferons by:
Injection as is normal for treating MS.
Nebulizer so that interferons can be introduce directly to the lung.
Nazel droplets direct to the nazal passageway.
I have posted below a link to Dr John Campbell who asses Synairgens recent succesful phase 2 trail results. This is not a ramp of that stock as I actually have my reservations about how they intend to get phase 3 sorted. They certainly have along way to go before approval. I am actually interested in the science and moreso what you all make of it. Further I am trying to get my head around the science here which seems far more complicated.
If you have seen this already, please ignore and apologies.
https://www.youtube.com/watch?v=wqDd7ixh184
its adjuvant is driving that i would suggest
so this Vax is showing strong Bias of its CD4 to .. Th1
https://ir.novavax.com/news-releases/news-release-details/novavax-announces-positive-phase-1-data-its-covid-19-vaccine
NVX-CoV2373 induced neutralization titers in 100% of participants; 5 µg adjuvanted dose group peak GMT: 3,906 (95% CI: 2,556; 5,970).
All subjects developed anti-spike IgG antibodies after a single dose of vaccine, many of them also developing wild-type virus neutralizing antibody responses, and after Dose 2, 100% of participants developed wild-type virus neutralizing antibody responses. Both anti-spike IgG and viral neutralization responses compared favorably to responses from patients with clinically significant COVID-19 disease. Importantly, the IgG antibody response was highly correlated with neutralization titers, demonstrating that a significant proportion of antibodies were functional.
Matrix-M™ adjuvant induced robust polyfunctional CD4+ T cell responses.
The adjuvant was dose-sparing, with the lower 5 µg dose of NVX-CoV2373 performing comparably with the 25 µg dose. Cellular immune responses were measured in a subset of participants, and NVX-CoV2373 induced antigen-specific polyfunctional CD4+ T cell responses with a strong bias toward the Th1 phenotype (IFN-g, IL-2, and TNF-a).
actually ... it might not if its Th2 ...
Burble help
pretty sure a neutralizing antibody .... secretes nothing . it cognitive CD4 will ..
another bit of research which i did not know
"" All interferons inhibit viral replication by interfering with the transcription of viral nucleic acid. ""
they are talking about ..... Interferon gamma (IFN?) this is what Scancell High Avidity T cells produce copious qty off ....
They are have whats called a Th1 profile ... this induces high inflammatory response (interferon)
https://www.bloomberg.com/news/articles/2020-09-24/covid-doctors-follow-dna-trail-to-potential-immune-treatment
This just popped up on my phone. There are some interesting points here.